GlassScriptPhysician profile
Heather R Echols
NPI 1306070818
$5,268.92
in general payments reported to CMS, 2019-2025
22 companies · $702 in 2025
The $702 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $488 · 2021: $710 · 2022: $820 · 2023: $926 · 2024: $889 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.65 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,333.46 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $916.15 | 2020-2025 | Xifaxan |
| Pfizer INC. | $884.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $544.92 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $382.48 | 2023-2025 | |
| Janssen Biotech, INC. | $246.52 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $227.26 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $122.34 | 2023-2025 | Stelara, Tremfya |
| Boston Scientific Corporation | $105.94 | 2019-2025 | Orca |
| Regeneron Healthcare Solutions, INC. | $97.47 | 2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $78.89 | 2019 | |
| Merck Sharp & Dohme LLC | $70.83 | 2019-2023 | Dificid |
| Cook Medical LLC | $59.87 | 2019 | |
| Evoke Pharma, INC. | $30.03 | 2021 | |
| Ironwood Pharmaceuticals, INC | $27.00 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $26.56 | 2022 | |
| Mauna Kea Technologies, INC. | $25.79 | 2025 | |
| Gilead Sciences, INC. | $22.89 | 2024 | |
| Amgen INC. | $22.16 | 2025 | Uplizna |
| Phathom Pharmaceuticals, INC. | $19.38 | 2025 | Voquezna |
| Allergan, INC. | $12.28 | 2019 | |
| Axonics, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Echols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.